Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1989 1
1990 1
1991 1
1993 2
1994 2
1997 1
1999 4
2000 1
2002 2
2003 2
2004 2
2006 2
2007 2
2008 1
2010 2
2014 2
2015 2
2016 4
2017 1
2018 3
2019 2
2020 3
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Childhood Hodgkin Lymphoma"
Page 1
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Davis KL, et al. Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192573 Free PMC article. Clinical Trial.
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin …
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the followin …
Chlorambucil-induced seizures.
Salloum E, Khan KK, Cooper DL. Salloum E, et al. Cancer. 1997 Mar 1;79(5):1009-13. doi: 10.1002/(sici)1097-0142(19970301)79:5<1009::aid-cncr18>3.0.co;2-5. Cancer. 1997. PMID: 9041164 Review.
Underlying diseases included nephrotic syndrome (n = 12 cases), solid tumors (n - 10 cases), non-Hodgkin's lymphoma (n = 3 cases), and chronic lymphocytic leukemia (n = 1 case). ...In adults without a seizure history, seizures were observed only in patients t …
Underlying diseases included nephrotic syndrome (n = 12 cases), solid tumors (n - 10 cases), non-Hodgkin's lymphoma (n = 3 cas …
Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
Miles RR, Shah RK, Frazer JK. Miles RR, et al. Br J Haematol. 2016 May;173(4):582-96. doi: 10.1111/bjh.14011. Epub 2016 Mar 11. Br J Haematol. 2016. PMID: 26969846 Free PMC article. Review.
Molecular genetic abnormalities are ubiquitous in non-Hodgkin lymphoma (NHL), but genetic changes are not yet used to define specific lymphoma subtypes. Certain recurrent molecular genetic abnormalities in NHL underlie molecular pathogenesis and/or are …
Molecular genetic abnormalities are ubiquitous in non-Hodgkin lymphoma (NHL), but genetic changes are not yet used to define s …
Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study).
Rahiman EA, Bakhshi S, Deepam Pushpam, Ramamoorthy J, Das A, Ghara N, Kalra M, Kapoor G, Meena JP, Siddaigarhi S, Thulkar S, Sharma MC, Srinivasan R, Trehan A. Rahiman EA, et al. Pediatr Hematol Oncol. 2022 Aug;39(5):391-405. doi: 10.1080/08880018.2021.2002485. Epub 2022 Jan 3. Pediatr Hematol Oncol. 2022. PMID: 34978257
The literature on B-non-Hodgkin lymphoma (NHL) in India is restricted to individual hospital data. ...Treatment-related mortality (TRM), relapse/progression and abandonment were 14.3%, 14.5%, and 8.4%, respectively. Bone marrow positivity, stage IV disease, a …
The literature on B-non-Hodgkin lymphoma (NHL) in India is restricted to individual hospital data. ...Treatment-related mortal …
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Jakša R, Karolová J, Svatoň M, Kazantsev D, Grajciarová M, Pokorná E, Tonar Z, Klánová M, Winkowska L, Maláriková D, Vočková P, Forsterová K, Renešová N, Dolníková A, Nožičková K, Dundr P, Froňková E, Trněný M, Klener P. Jakša R, et al. Lab Invest. 2022 Sep;102(9):957-965. doi: 10.1038/s41374-022-00784-w. Epub 2022 Apr 29. Lab Invest. 2022. PMID: 35488033 Free PMC article.
Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. ...WES data confirmed that PDXs maintained the genetic heterogeneity with the original primary lymphoma cells. In contrast, IHC analysis revealed the following recurrently obse …
Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. ...WES data confirmed that PDXs maintained the geneti …
Relapse localization in Danish pediatric patients with Hodgkin lymphoma.
Lundgaard AY, Hjalgrim LL, Dejanovic D, Berthelsen AK, Schomerus E, Wendtland P, Specht L, Maraldo MV. Lundgaard AY, et al. Acta Oncol. 2021 May;60(5):658-666. doi: 10.1080/0284186X.2021.1881817. Epub 2021 Mar 12. Acta Oncol. 2021. PMID: 33710948
BACKGROUND: Pediatric Hodgkin lymphoma (pHL) is highly curable. However, a minority experience relapse and are subjected to toxic salvage regimens. ...The lymphoma volumes involved at diagnosis and at relapse were contoured on the patients' original scans. .. …
BACKGROUND: Pediatric Hodgkin lymphoma (pHL) is highly curable. However, a minority experience relapse and are subjected to to …
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
Giulino-Roth L, O'Donohue T, Chen Z, Trippett TM, Klein E, Kernan NA, Kobos R, Prockop SE, Scaradavou A, Shukla N, Steinherz PG, Moskowitz AJ, Moskowitz CH, Boulad F. Giulino-Roth L, et al. Leuk Lymphoma. 2018 Aug;59(8):1861-1870. doi: 10.1080/10428194.2017.1403601. Epub 2017 Nov 29. Leuk Lymphoma. 2018. PMID: 29183202 Free PMC article.
To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer …
To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem ce …
Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
Jan MRU, Saeed H, Abubakar M, Wali RM. Jan MRU, et al. Leuk Lymphoma. 2020 Dec;61(14):3369-3377. doi: 10.1080/10428194.2020.1817434. Epub 2020 Sep 13. Leuk Lymphoma. 2020. PMID: 32924702
This study aimed to determine response rates, overall survival (OS), event-free survival (EFS) and toxicity profile of an outpatient chemotherapy regimen based on gemcitabine and vinorelbine (GV) for relapsed childhood Hodgkin lymphoma (HL). This was a retros …
This study aimed to determine response rates, overall survival (OS), event-free survival (EFS) and toxicity profile of an outpatient chemoth …
Mortality and Cancer Incidence in Carriers of Balanced Robertsonian Translocations: A National Cohort Study.
Schoemaker MJ, Jones ME, Higgins CD, Wright AF; United Kingdom Clinical Cytogenetics Group; Swerdlow AJ. Schoemaker MJ, et al. Am J Epidemiol. 2019 Mar 1;188(3):500-508. doi: 10.1093/aje/kwy266. Am J Epidemiol. 2019. PMID: 30535276 Free PMC article.
Cancer incidence was higher for non-Hodgkin lymphoma (standardized incidence ratio (SIR) = 1.90, 95% CI: 1.01, 3.24) and childhood leukemia (SIR = 14.5, 95% CI: 1.75, 52.2), the latter particularly in rob(15;21) carriers (SIR = 447.8, 95% CI: 11.3, 2,495). .. …
Cancer incidence was higher for non-Hodgkin lymphoma (standardized incidence ratio (SIR) = 1.90, 95% CI: 1.01, 3.24) and ch …
Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L, Miltényi Z, Illés Á. Pinczés L, et al. J Cancer Res Clin Oncol. 2018 May;144(5):935-943. doi: 10.1007/s00432-018-2613-9. Epub 2018 Feb 21. J Cancer Res Clin Oncol. 2018. PMID: 29468437
PURPOSE: Majority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happening 5 or more years after first diagnosis is rare events. ...CONCLUSION: Late relapse of HL presents with clinical characteristics very sim …
PURPOSE: Majority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happe …
48 results